Skip to main content
Premium Trial:

Request an Annual Quote

Daniel O'Day, Sandra Horning, Michael Varney

Following Roche's successful tender offer for a majority of Foundation Medicine shares, Daniel O'Day, Sandra Horning, and Michael Varney have joined Foundation Medicine's board of directors.

O’Day is the chief operating officer of the Roche Pharmaceuticals division and a member of the Roche corporate executive committee, Horning is the global head of product development and chief medical officer for Roche's Genentech, and Varney is the head of Genentech research and early development.

The three new directors are joining five continuing directors: Foundation Medicine CEO Michael Pellini; Alexis Borisy, who will remain the board's chairman; Evan Jones; David Schenkein; and Krishna Yeshwant.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.